Theratechnologies inc.

Theratechnologies inc.

May 14, 2008 17:59 ET

Notice of Conference Call & Media Advisory: Theratechnologies Signs a Strategic Agreement to Explore the Use of Tesamorelin in an Additional Indication

MONTREAL, CANADA--(Marketwire - May 14, 2008) - Theratechnologies (TSX:TH) advises of an upcoming conference call and webcast to discuss the signing of a strategic agreement to explore the use of tesamorelin in an additional indication. The call will be moderated by Dr. Andrea Gilpin, Executive Director, IR & Communications, at Theratechnologies. Mr. Yves Rosconi, President and CEO, Dr. Pierre Caudrelier, Chief Medical Officer and Dr. Christian Marsolais, Vice President, Clinical Research, will also be participating.

The conference call will take place tomorrow, May 15, at 8:00 a.m. Eastern Time. Prior to the call, a press release will be issued at approximately 7:00 a.m.

May 15, 2008 conference call and webcast

For the conference call, interested participants are asked to dial the following numbers: 416-915-5765 or 1-800-814-4862 (toll free). Please call five minutes prior to the conference in order to ensure your participation. The webcast will be available on the Company's website at

A replay of the conference call will be available from May 15, 2008 at 10:00 a.m. to May 22, 2008 at 11:59 p.m. at the following number: 416-640-1917, pass code 21272300# or 1-877-289-8525, code 21272300#. The webcast will be posted for 30 days on the Company's website.

About Theratechnologies

Theratechnologies (TSX:TH) is a Canadian biopharmaceutical company that discovers innovative drug candidates in order to develop them and bring them to market. The Company targets unmet medical needs in financially attractive specialty markets. Its most advanced program is tesamorelin, now in a confirmatory Phase 3 clinical trial for a serious metabolic disorder known as HIV-associated lipodystrophy. The Company also has other projects at earlier stages of development.

Contact Information